Allogene Therapeutics, Inc. ALLO

Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026. Mr. Parker will continue to lead the finance organization through his retirement date as the Company conducts an exter

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September. Citi Biopharma Back to School Conference Wednesday, September 9 5:00 a.m. PT/8:00 a.m. ET Any available webcasts will be posted to the Company’s websi

Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Allogene Therapeutics (ALLO) remains attractive given its undemanding valuation and differentiated c

Moby summary of Allogene Therapeutics, Inc.'s Q2 2026 earnings call

Allogene Therapeutics Inc (ALLO) advances its allogeneic CAR-T pipeline with key regulatory milestones and strong trial momentum, while navigating solid tumor challenges and competitive pressures.

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation TherapyStrong Execution and Increased Investigator Interest Accelerated 2026 Site Activation Target by Six Months; Approximately 100 Sites Now Expected by Year-End, Further Supporting EnrollmentNext Update Anticipated in Mid-2027, with Trial Enrollment Expected to Be Completed by Year-End 2027

Conference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report second quarter 2026 financial results and provide a business update on August 12, 2026, after the close of the market. The annou

FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel’s Potential to Transform Disease Treatment in First-Line LBCL Consolidation Cema-Cel Induced Rapid and Substantial MRD Clearance of 58.3%, with a 97.7% Median Decrease in Plasma ctDNA at Day 45, Compared With a 26.6% Median Increase in the Observation ArmCema-Cel Was Well-Tolerated, With Most Patients Managed in the Outpatient Setting and No Hospitalizations for Treatment-Related Adverse Events FDA Also G

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All Responders Progression-Free at the Time of AnalysisResponses Range from 8 to 18+ Months, with Median Overall Survival Not Yet Reached Safety Profile was Manageable with Proactive Diagnostic and Management Strategies Effective in Mitigating IEC-HSALLO-316 Demons

A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or the start of a painful unwind.

Allogene Therapeutics is back in focus as its fair value estimate has been reset to US$8.49 from US$7.47, alongside a mix of price target moves across the Street. Some analysts have raised targets by US$2 to US$4 after the ALPHA3 trial update and refreshed models, while others have trimmed targets by around US$1 as they weigh execution risk and funding needs. Read on to see how to track these shifting views and what signals to watch as the Allogene Therapeutics story continues to...